Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;111:2792-2797
Published online before print May 23, 2005, doi: 10.1161/CIRCULATIONAHA.104.473629
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
111/21/2792    most recent
CIRCULATIONAHA.104.473629v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rieder, E.
Right arrow Articles by Weigel, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rieder, E.
Right arrow Articles by Weigel, G.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Valvular heart disease
Right arrow CV surgery: valvular disease
Right arrowRelated Article

(Circulation. 2005;111:2792-2797.)
© 2005 American Heart Association, Inc.


Valvular Heart Disease

Tissue Engineering of Heart Valves

Decellularized Porcine and Human Valve Scaffolds Differ Importantly in Residual Potential to Attract Monocytic Cells

Erwin Rieder, MD; Gernot Seebacher, MD; Marie-Theres Kasimir, MD; Eva Eichmair, MS; Birgitta Winter, MS; Barbara Dekan, MS; Ernst Wolner, MD; Paul Simon, MD; Guenter Weigel, MD

From the Department of Cardiothoracic Surgery and Ludwig-Boltzmann-Institute for Cardiosurgical Research, Medical University of Vienna, Vienna, Austria.

Correspondence to Guenter Weigel, MD, Department of Cardiothoracic Surgery, Medical University of Vienna, AKH, Waehringer Guertel 18-20, 1090 Vienna, Austria. E-mail guenter.weigel{at}meduniwien.ac.at

Received May 7, 2004; revision received December 28, 2004; accepted February 4, 2005.

Background— Tissue-engineered or decellularized heart valves have already been implanted in humans or are currently approaching the clinical setting. The aim of this study was to examine the migratory response of human monocytic cells toward decellularized porcine and human heart valves, a pivotal step in the early immunologic reaction.

Methods and Results— Porcine and human pulmonary valve conduits were decellularized, and migration of U-937 monocytic cells toward extracted heart valve proteins was examined in a transmigration chamber in vitro. Homogenized tissue specimens were size fractionated by SDS-PAGE. The decellularization procedure effectively reduced the migration of human monocytes toward all heart valve tissue. However, only the antigen reduction of human pulmonary valves abolished the monocytic response (wall, 0.88±0.19% versus 30.20±3.93% migrated cells [mean±SEM]; cusps, 0.10±0.06% versus 10.24±1.83%) and was significantly lower (P<0.05) than that of the decellularized porcine equivalent (wall, 5.03±0.14% versus 24.31±2.38%; cusps, 3.18±0.38% versus 10.24±1.83%). SDS-PAGE of the pulmonary heart valve tissue revealed that considerable amounts of proteins with different molecular weights that were not detected in the human equivalent remain in the decellularized porcine heart valve.

Conclusions— We describe for the first time that the remaining potential of decellularized pulmonary heart valves to attract monocytic cells depends strongly on whether porcine or human scaffolds were used. These findings will have an important impact on further investigations in the field of heart valve tissue engineering.


Key Words: immunology • inflammation • tissue engineering • valves


Related Article:

Tissue Engineering of Heart Valves: Decellularized Valve Scaffolds
Richard A. Hopkins
Circulation 2005 111: 2712-2714. [Extract] [Full Text]



This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
E. Hickey, S. M. Langley, O. Allemby-Smith, S. A. Livesey, and J. L. Monro
Subcoronary Allograft Aortic Valve Replacement: Parametric Risk-Hazard Outcome Analysis to a Minimum of 20 Years
Ann. Thorac. Surg., November 1, 2007; 84(5): 1564 - 1570.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. H. Goldbarg, S. Elmariah, M. A. Miller, and V. Fuster
Insights Into Degenerative Aortic Valve Disease
J. Am. Coll. Cardiol., September 25, 2007; 50(13): 1205 - 1213.
[Abstract] [Full Text] [PDF]


Home page
ICVTSHome page
G. Van Nooten, P. Somers, M. Cornelissen, S. Bouchez, F. Gasthuys, E. Cox, L. Sparks, and K. Narine
Acellular porcine and kangaroo aortic valve scaffolds show more intense immune-mediated calcification than cross-linked Toronto SPV(R) valves in the sheep model
Interactive CardioVascular and Thoracic Surgery, October 1, 2006; 5(5): 544 - 549.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Cebotari, A. Lichtenberg, I. Tudorache, A. Hilfiker, H. Mertsching, R. Leyh, T. Breymann, K. Kallenbach, L. Maniuc, A. Batrinac, et al.
Clinical Application of Tissue Engineered Human Heart Valves Using Autologous Progenitor Cells
Circulation, July 4, 2006; 114(1_suppl): I-132 - I-137.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Lichtenberg, I. Tudorache, S. Cebotari, M. Suprunov, G. Tudorache, H. Goerler, J.-K. Park, D. Hilfiker-Kleiner, S. Ringes-Lichtenberg, M. Karck, et al.
Preclinical Testing of Tissue-Engineered Heart Valves Re-Endothelialized Under Simulated Physiological Conditions
Circulation, July 4, 2006; 114(1_suppl): I-559 - I-565.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
C. Schreiber, S. Sassen, M. Kostolny, J. Horer, J. Cleuziou, M. Wottke, K. Holper, F. Fend, A. Eicken, and R. Lange
Early graft failure of small-sized porcine-valved conduits in reconstruction of the right ventricular outflow tract.
Ann. Thorac. Surg., July 1, 2006; 82(1): 179 - 185.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
U.A. Stock, I. Degenkolbe, T. Attmann, K. Schenke-Layland, S. Freitag, and G. Lutter
Prevention of device-related tissue damage during percutaneous deployment of tissue-engineered heart valves
J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1323 - 1330.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
F. Juthier, A. Vincentelli, J. Gaudric, D. Corseaux, O. Fouquet, C. Calet, T. L. Tourneau, V. Soenen, C. Zawadzki, O. Fabre, et al.
Decellularized heart valve as a scaffold for in vivo recellularization: Deleterious effects of granulocyte colony-stimulating factor
J. Thorac. Cardiovasc. Surg., April 1, 2006; 131(4): 843 - 852.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. A. Hopkins
Tissue Engineering of Heart Valves: Decellularized Valve Scaffolds
Circulation, May 31, 2005; 111(21): 2712 - 2714.
[Full Text] [PDF]